Ascendiant Capital Markets started coverage on shares of Aclarion (NASDAQ:ACON – Free Report) in a research note released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $1.60 price objective on the stock.
Aclarion Stock Performance
Shares of NASDAQ:ACON opened at $0.31 on Monday. The company has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.70. Aclarion has a 12-month low of $0.27 and a 12-month high of $10.24.
Aclarion (NASDAQ:ACON – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. Aclarion had a negative return on equity of 2,554.98% and a negative net margin of 10,246.33%.
Hedge Funds Weigh In On Aclarion
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Featured Articles
- Five stocks we like better than Aclarion
- Dividend Payout Ratio Calculator
- First Solar Stock: The Dawn of a New Rally in Share Prices
- 3 Warren Buffett Stocks to Buy Now
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Do ETFs Pay Dividends? What You Need to Know
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.